Volume 24 Issue 3
Mar.  2026
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2026  >  24(3): 468-471
FAN Dekang, LING Yingchun, LYU Pingping, WANG Haiyan. Clinical study of sodium valproate sustained release tablets combined with risperidone in the treatment of mental and behavioral symptoms of Alzheimer ' s disease[J]. Chinese Journal of General Practice, 2026, 24(3): 468-471. doi: 10.16766/j.cnki.issn.1674-4152.004421
Citation: FAN Dekang, LING Yingchun, LYU Pingping, WANG Haiyan. Clinical study of sodium valproate sustained release tablets combined with risperidone in the treatment of mental and behavioral symptoms of Alzheimer ' s disease[J]. Chinese Journal of General Practice, 2026, 24(3): 468-471. doi: 10.16766/j.cnki.issn.1674-4152.004421
shu

Clinical study of sodium valproate sustained release tablets combined with risperidone in the treatment of mental and behavioral symptoms of Alzheimer ' s disease

doi: 10.16766/j.cnki.issn.1674-4152.004421
  • 1.

    Department of Psychiatry, Yongkang Third People ' s Hospital, Yongkang, Zhejiang 321300, China

Funds:

 2022KY1309

  • Received Date: 2025-11-17
    Available Online: 2026-06-02
    Abstract
  •   Objective  To investigate the efficacy and safety of sodium valproate sustained-release tablets combined with risperidone in the treatment of Alzheimer ' s disease (AD) with psychobehavioral symptoms (BPSD), providing evidence for clinical treatment strategies.  Methods  A total of 186 patients with AD with BPSD admitted to Yongkang Third People ' s Hospital from May 2023 to April 2025 were randomly divided into group A and group B. 93 cases in group A were treated with risperidone, and 93 cases in group B were treated with sodium valproate sustained-release tablets combined with risperidone. The cognitive function, mental and behavioral symptoms, activities of daily living, clinical efficacy, and adverse reactions of the two groups were observed.  Results  The Montreal cognitive assessment (MoCA) and mini-mental state examination (MMSE) scores of the two groups were improved after treatment (P < 0.05), and the MoCA and MMSE scores of group B were higher than those of group A (P < 0.05). After treatment, the behavioral pathology in the Alzheimer ' s disease rating scale (BEHAVE-AD) and neuropsychiatric inventory (NPI) scores in the two groups were decreased (P < 0.05), and the BEHAVE-AD and NPI scores in group B were lower than those in group A (P < 0.05). After treatment, the ADL scores of the two groups were improved (P < 0.05), and the ADL scores of group B were higher than those of group A (P < 0.05). The total effective rate of group B was 86.02% (80/93), which was higher than 74.19% (69/93) of group A (χ2=4.082, P=0.043). The incidence of adverse reactions was 12.90% (12/93) in group A and 10.75% (10/93) in group B, and there was no significant difference between the two groups (P>0.05).  Conclusion  Sodium valproate sustained-release tablets combined with risperidone in the treatment of AD with BPSD can improve the cognitive function, mental behavior-related symptoms, and the ability of daily life of patients, improve the clinical efficacy, and perform well in terms of safety, which is worthy of promotion.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    SINGH A K, MALVIYA R, PRAKASH A, et al. Neuropsychiatric manifestations in Alzheimer ' s disease patients: genetics and treatment options[J]. CNS Neurol Disord Drug Targets, 2024, 23(1): 39-54.
    [2]
    冯靓瑶, 刘敏. 影响阿尔茨海默病患者家庭照料者预期性悲伤水平的危险因素及干预对策的构建[J]. 中国基层医药, 2025, 32(5): 757-762.

    FENG L Y, LIU M. Identification of risk factors affecting anticipatory grief levels in family caregivers of patients with Alzheimer ' s disease and development of intervention strategies[J]. Chinese Journal of Primary Medicine and Pharmacy, 2025, 32(5): 757-762.
    [3]
    李坷, 刘崇. 阿尔茨海默病患者精神行为症状发生情况及影响因素分析[J]. 国际精神病学杂志, 2024, 51(6): 1831-1835.

    LI K, LIU C. Analysis of the occurrence and influential factors of psychobehavioral symptoms in patients with Alzheimer ' s disease[J]. Journal Of International Psychiatry, 2024, 51(6): 1831-1835.
    [4]
    谷红丽, 栾婷婷, 赵广春, 等. 丁苯酞治疗阿尔茨海默病精神行为症状的疗效观察[J]. 国际精神病学杂志, 2024, 51(4): 1194-1196.

    GU H L, LUAN T T, ZHAO G C, et al. Observation on the therapeutic effect of butylphthalide in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease[J]. Journal Of International Psychiatry, 2024, 51(4): 1194-1196.
    [5]
    ROUGHLEY M, MENA C, HOWARD R, et al. Guiding safer risperidone prescribing in Alzheimer ' s disease with therapeutic drug monitoring[J]. Br J Clin Pharmacol, 2023, 89(7): 2316-2321. doi: 10.1111/bcp.15692
    [6]
    ZHOU J X, WEI Z P, HUANG W, et al. Multiple adverse reactions associated with the use of second-generation antipsychotics in people with Alzheimer ' s disease: a pharmacovigilance analysis based on the FDA adverse event reporting system[J]. Ann Pharmacother, 2025, 59(3): 213-222. doi: 10.1177/10600280241271093
    [7]
    庄俊鸿, 云天, 王年臻, 等. 丙戊酸钠与拉莫三嗪联用对原发性癫痫患者外周血TNF-αIL-2的影响研究[J]. 河北医学, 2018, 24(6): 1007-1012.

    ZHUANG J H, YUN T, WANG N Z, et al. Effect of valproate combined with lamotrigine on TNF-and IL-2 in peripheral blood of patients with primary epilepsy[J]. Hebei Medicine, 2018, 24(6): 1007-1012.
    [8]
    王娟, 马超英, 岳雅君. 对比奥氮平、阿立哌唑和利培酮治疗阿尔茨海默病的临床效果及对认知功能的影响[J]. 中国老年学杂志, 2023, 43(21): 5241-5244.

    WANG J, MA C Y, YUE Y J. Comparison of clinical effects of olanzapine, aripiprazole and risperidone in the treatment of Alzheimer ' s disease and their influences on cognitive function[J]. Chinese Journal of Gerontology, 2023, 43(21): 5241-5244.
    [9]
    周哲明, 李芳, 易庆, 等. 阿立哌唑治疗阿尔茨海默病伴精神障碍患者的血药浓度监测分析[J]. 中国药物与临床, 2025, 25(2): 83-86.

    ZHOU Z M, LI F, YI Q, et al. Blood concentration monitoring analysis of aripiprazole treatment in patients with Alzheimer's disease with mental disorders[J]. Chinese Remedies & Clinics, 2025, 25(2): 83-86.
    [10]
    王云霞, 李旺俊. 甘露特钠联合多奈哌齐治疗阿尔茨海默病的临床研究[J]. 现代药物与临床, 2022, 37(10): 2258-2262.

    WANG Y X, LI W J. Clinical study on sodium oligomannate combined with donepezil in treatment of Alzheimer's disease[J]. Drugs & Clinic, 2022, 37(10): 2258-2262.
    [11]
    SELF W K, HOLTZMAN D M. Emerging diagnostics and therapeutics for Alzheimer disease[J]. Nat Med, 2023, 29(9): 2187-2199. doi: 10.1038/s41591-023-02505-2
    [12]
    SINGH B, DAY C M, ABDELLA S, et al. Alzheimer ' s disease current therapies, novel drug delivery systems and future directions for better disease management[J]. J Control Release, 2024, 367: 402-424.
    [13]
    张烈, 凌迎春, 高钢梅. 基于近红外脑功能检测研究多奈哌齐联合认知康复治疗阿尔茨海默病的疗效[J]. 中华全科医学, 2024, 22(11): 1872-1875. doi: 10.16766/j.cnki.issn.1674-4152.003753

    ZHANG L, LING Y C, GAO G M. Efficacy of donepezil combined with cognitive rehabilitation in treating Alzheimer ' s disease based on near-infrared brain function detection[J]. Chinese Journal of General Practice, 2024, 22(11): 1872-1875. doi: 10.16766/j.cnki.issn.1674-4152.003753
    [14]
    程丹, 周宇, 吴传东. 阿立哌唑和利培酮治疗精神分裂症患者的效果和不良反应分析[J]. 国际精神病学杂志, 2024, 51(3): 716-719.

    CHENG D, ZHOU Y, WU C D. Analysis of the efficacy and adverse reactions of aripiprazole and risperidone in the treatment of schizophrenia[J]. Journal Of International Psychiatry, 2024, 51(3): 716-719.
    [15]
    胡乃启, 张朋, 宋宁, 等. 利培酮联合奥氮平对首发精神分裂症患者血清同型半胱氨酸水平和认知功能及临床疗效的影响[J]. 河北医学, 2016, 22(11): 1837-1839.

    HU N Q, ZHANG P, SONG N, et al. To investigate the effect of risperidone combined with olanzapine on serum homocysteine level, cognitive function and clinical efficacy in patients with first-episode schizophrenia[J]. Hebei Medicine, 2016, 22(11): 1837-1839.
    [16]
    SORIAL M E S, ABDELGHANY R M, EL SAYED N S E D. Modulation of the cognitive impairment associated with Alzheimer ' s disease by valproic acid: possible drug repurposing[J]. Inflammopharmacology, 2025, 33(4): 2083-2094. doi: 10.1007/s10787-025-01695-0
    [17]
    ITO Y, TAKEDA S, MOROI S, et al. Antiepileptic drugs modulate Alzheimer-related tau aggregation in a neuronal activity-independent manner[J]. Dement Geriatr Cogn Disord, 2023, 52(2): 108-116. doi: 10.1159/000529915
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1) PDF downloads(0) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return